The Accupril Canadian Clinical Evaluation and Patient Teaching study - ACCEPT
This is a prospective surveillance study to determine the efficacy and safety of quinapril as monotherapy or in conjunction with other antihypertensive medications at lowering blood pressure among Canadian patients with essential hypertension.
Quinapril is both safe and effective both as monotherapy and as part of an antihypertensive regimen among a large sample of community-dwelling Canadian patients with essential hypertension.
Patients Enrolled: 3745
Mean Follow Up: 6 months
Mean Patient Age: Median 56 years
Patients with essential hypertension judged by their phyisicans to be suitable candidates for ACE inhibitor therapy.
- Stabilized blood pressure defined as a level at which the treating physician deemed that no further adjustment of medication was clinically necessary.
- Change in systolic and diastolic blood pressure at 3 and 6 months
- Association between level of detail on the adverse event form provided to patients and reporting of adverse events
- Association between reported side effects and use of quinapril, with subgroup analysis by dose
- Quinapril (Accupril), at 10 mg daily, titrated to a maximum of 40 mg daily, based on blood pressure response
- A more detailed form listing side effects compared with a less detailed form
The use of other antihypertensive medications was left to the discretion of the the physician
- At 3 months, 77% of patients had attained a "stabilized" blood pressure
- At 6 months, 84% had attained a "stabilized" blood pressure
- 26.2% of patients reported at least one adverse event
- Adverse events were more often associated with patient having received the more detailed side effect form (30% vs 24%, p=0.004)
In actual clinical practice among community-dwelling Canadian patients with essential hypertension, quinapril seemed safe and effective at decreasing blood pressure either alone or in combination with other antihypertensive medications.
Larochelle P, et al. A Postmarketing Surveillance Evaluation of Quinapril in 3742 Canadian Hypertensive Patients: The ACCEPT Study. Clinical Therapeutics 1994; 5:838-53.
Keywords: Canada, Tetrahydroisoquinolines, Blood Pressure, Hypertension
< Back to Listings